A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Bristol-Myers Squibb · NCT06875960
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 4
- Target enrollment
- 35
- US sites recruiting
- 2
- Study start
- February 24, 2026
- Record last updated
- September 9, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this study is to allow the continued administration of Deucravacitinib in participants with Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) who have completed study IM011074 or Study IM011132
Being studied: BMS-986165
Conditions: Systemic Lupus Erythematosus (SLE); Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Participants must have completed Study IM011074 or Study IM011132 through the protocol-required treatment period.
- Participants must be, based on the physician's medical judgement, likely to receive benefit from receiving treatment with deucravacitinib.
- Participants must have received IP within 60 days of enrollment. Exceptions may be granted based upon consultation with BMS.
Exclusion Criteria
- Participants must not have any disease or medical condition that, in the opinion of the physician, would make the subject unsuitable for this protocol, would interfere with the interpretation of subject safety or considered unsuitable by the physician for any other reason.
- Participants must not have any evidence of active Tuberculosis (TB).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Recruiting US locations
New York University School Of Medicine
New York, NY 10155
Site contact: Amit Saxena, Site 0002 · 646-501-7387
Oklahoma Medical Research Foundation
Oklahoma City, OK 73104
Site contact: Cristina Arriens, Site 0004 · 405-271-7805
Study contacts (from the official record)
- BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
- First line of the email MUST contain NCT # and Site #.